Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

67%

4 trials in Phase 3/4

Results Transparency

33%

2 of 6 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 3

4(66.7%)

Phase 2

2(33.3%)

6Total

Phase 3(4)

Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT01710007Phase 3Completed

Efficacy and Safety Study of Pitavastatin for Hypercholesterolemia

Role: lead

NCT01370811Phase 2Completed

A Relative Efficacy and Safety Study of OC Oral Solution for Sialorrhoea in Patients With Parkinson's Disease

Role: lead

NCT02467608Phase 2Completed

Efficacy of HUEXC030 in Subjects With Pulmonary Tuberculosis

Role: lead

NCT04643093Phase 3Completed

Compare the Efficacy and Safety of 1PC111 With Pitavastatin and Ezetimibe in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia

Role: lead

NCT02704390Phase 3Completed

Evaluate Long-term Safety and Efficacy of ORADUR®-Methylphenidate in Children and Adolescents With ADHD

Role: lead

NCT02450890Phase 3Completed

Evaluate Safety and Efficacy of ORADUR®-Methylphenidate in Children and Adolescents With ADHD

Role: lead

All 6 trials loaded